{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:21:38Z","timestamp":1783650098779,"version":"3.55.0"},"reference-count":22,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2023,12,19]]},"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1136\/thorax-2023-221167","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T18:26:32Z","timestamp":1706898392000},"page":"295-296","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Use of inhaled treprostinil in patients with interstitial lung disease and pulmonary hypertension: to boldly go where no other pulmonary vasodilator has gone before?"],"prefix":"10.1136","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2241-7523","authenticated-orcid":false,"given":"Lucilla","family":"Piccari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4287-1173","authenticated-orcid":false,"given":"Stephen John","family":"Wort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"2025042101250957000_79.4.295.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00078411"},{"key":"2025042101250957000_79.4.295.2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1159\/000524263","article-title":"The effect of borderline pulmonary hypertension on survival in chronic lung disease","volume":"101","author":"Piccari","year":"2022","journal-title":"Respiration"},{"key":"2025042101250957000_79.4.295.3","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12127","article-title":"Clinical significance of pulmonary hypertension in interstitial lung disease: a consensus statement from the pulmonary vascular research Institute \u2019 s innovative drug development initiative \u2014 group 3 pulmonary hypertension","volume":"12","author":"Nikkho","year":"2022","journal-title":"Pulm Circ"},{"key":"2025042101250957000_79.4.295.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01914-2018"},{"key":"2025042101250957000_79.4.295.5","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000984"},{"key":"2025042101250957000_79.4.295.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008470"},{"key":"2025042101250957000_79.4.295.7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02414-2022","article-title":"Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study","volume":"61","author":"Waxman","year":"2023","journal-title":"Eur Respir J"},{"key":"2025042101250957000_79.4.295.8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chest.2022.09.007","article-title":"Inhaled treprostinil dosage in pulmonary hypertension associated with interstitial lung disease and its effects on clinical outcomes","volume":"163","author":"Nathan","year":"2023","journal-title":"Chest"},{"key":"2025042101250957000_79.4.295.9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1164\/rccm.202107-1766OC","article-title":"Efficacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to Parenchymal lung disease in the INCREASE trial","volume":"205","author":"Nathan","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025042101250957000_79.4.295.10","first-page":"302","article-title":"Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality","volume":"79","author":"Nathan","year":"2024","journal-title":"Thorax"},{"key":"2025042101250957000_79.4.295.11","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1080\/03610929108830654","article-title":"Correcting for non-compliance in randomized trials using rank preserving structural failure time models","volume":"20","author":"Robins","year":"1991","journal-title":"Commun Stat"},{"key":"2025042101250957000_79.4.295.12","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"2025042101250957000_79.4.295.13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/resp.14378","article-title":"Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: a Bayesian retrospective observational cohort study","volume":"28","author":"Dawes","year":"2023","journal-title":"Respirology"},{"key":"2025042101250957000_79.4.295.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002110"},{"key":"2025042101250957000_79.4.295.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022"},{"key":"2025042101250957000_79.4.295.16","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2B study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025042101250957000_79.4.295.17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.healun.2021.02.006","article-title":"Impact of lung morphology on clinical outcomes with Riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: a post hoc subgroup analysis of the RISE-IIP study","volume":"40","author":"Nathan","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2025042101250957000_79.4.295.18","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.2.9810008"},{"key":"2025042101250957000_79.4.295.19","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study","volume":"9","author":"Nathan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025042101250957000_79.4.295.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2025042101250957000_79.4.295.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-19294-1","article-title":"Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation","volume":"8","author":"Lambers","year":"2018","journal-title":"Sci Rep"},{"key":"2025042101250957000_79.4.295.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001310","article-title":"Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis","volume":"9","author":"Nathan","year":"2022","journal-title":"BMJ Open Respir Res"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2023-221167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T10:59:21Z","timestamp":1745233161000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2023-221167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,15]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/thorax-2023-221167"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2023-221167","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]}}}